

Lung Cancer™

U P D A T E

An Audio Review Journal for Nurses

EDITOR

Neil Love, MD

FACULTY

Ann Fish-Steagall, RN, BSN, OCN

Rogério C Lilenbaum, MD

Additional comments by three patients with lung cancer from Dr Lilenbaum's practice



STATEMENT OF NEED/TARGET AUDIENCE

Lung cancer is the leading cause of cancer mortality in the United States in both men and women. Chemotherapy, surgery and radiation therapy have had a modest effect on patient outcomes; however, recent improvements have been seen in time to progression and survival in lung cancer clinical trials. Research findings and ongoing clinical trials lead to the continuous emergence of new drugs and therapies and changes in the indications for existing treatments. To offer their patients the best care possible, oncology nurses need to be aware of ongoing research and changes in cancer care so as to include the widening array of therapeutic options for cancer patients into their everyday patient management decisions. To assist with meeting this need, *Lung Cancer Update* for Registered Nurses provides an overview of the latest research developments in lung cancer and the opinions of oncology nurses, patients and research leaders with experience and expertise in the field.

PURPOSE STATEMENT

To present the most current research developments in lung cancer and to provide the perspectives of medical oncologists, oncology nurses and patients on the diagnosis and treatment of lung cancer.

EDUCATIONAL OBJECTIVES FOR THIS ISSUE OF *LUNG CANCER UPDATE* FOR NURSES

- Describe the types and stages of lung cancer and the stage-based modalities utilized in the cancer.
- Discuss nursing management of disease-related symptoms and treatment side effects.
- Identify and counsel patients appropriate for treatment with adjuvant chemotherapy.
- Discuss key clinical trials in lung cancer in the adjuvant and metastatic settings.
- Discuss social stigma related to lung cancer and the impact on patients and healthcare professionals.
- Describe nursing interventions based on the biopsychosocial model in caring for patients with lung cancer.

ACCREDITATION STATEMENTS

CNA/ANCC

This educational activity for 3.1 contact hours is provided by Postgraduate Institute for Medicine (PIM). PIM is an approved provider of continuing education by the Colorado Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.

California Board of Registered Nursing

Postgraduate Institute for Medicine is approved by the California Board of Registered Nursing, Provider Number 13485, for 3.1 contact hours.

A statement of credit will be issued only upon receipt of a completed activity Evaluation Form and a completed Post-test with a score of 70% or better. Your statement of credit will be mailed to you within three weeks.

HOW TO USE THIS CNE ACTIVITY

This is an audio CNE activity. This book contains a continuing nursing education post-test, and the corresponding website LungCancerUpdate.com/Nurses includes links to relevant full-text articles and abstracts. There are no fees for participating and receiving CNE credit for this activity. To receive credit during the period of July 2006 through July 2007, participants should read the learning objectives and faculty disclosures, listen to the CDs, review the internet references and complete the post-test and evaluation form located in the back of this book or on the LungCancerUpdate.com/Nurses website and mail or fax the evaluation form to Postgraduate Institute for Medicine.

Lung Cancer™

U P D A T E

FACULTY AFFILIATIONS



Ann Fish-Steagall, RN, BSN, OCN
Clinical Coordinator
Multidisciplinary Thoracic
Oncology Program
University of North Carolina
at Chapel Hill
Chapel Hill, North Carolina



Rogerio C Lilenbaum, MD
Clinical Associate Professor
of Medicine
University of Miami School of
Medicine
Director, Thoracic Oncology Program
The Mount Sinai Comprehensive
Cancer Center
Miami Beach, Florida

CONTENT VALIDATION AND DISCLOSURES

Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors, planners, managers and other individuals who are in a position to control the content of CNE activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high-quality CNE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CNE activity:

Ms Fish-Steagall — No financial interests or affiliations to disclose. **Dr Lilenbaum** — Consulting Fees: Genentech BioOncology; Contracted Research: Sanofi-Aventis.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this activity: Richard Kaderman, PhD, Neil Love, MD, Douglas Paley, Margaret Peng, Lilliam Sklaver Poltorack, PharmD and Kathryn Ault Ziel, PhD — no real or apparent conflicts of interest to report; Sally Bogert, RNC, WHCNP — shareholder of Amgen Inc. Research To Practice receives education grants from Abraxis Oncology, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer Pharmaceuticals Corporation/Onyx Pharmaceuticals Inc, Genentech BioOncology/OSI Pharmaceuticals Inc, Genomic Health Inc, Roche Laboratories Inc and Sanofi-Aventis, who have no influence on the content development of our educational activities.

The following PIM clinical content reviewers, Jan Hixon, RN, Linda Graham, RN and Trace Hutchison, PharmD state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interests related to the content of this CNE activity of any amount during the past 12 months.

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Postgraduate Institute for Medicine (PIM), Research To Practice and Sanofi-Aventis do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM, Research To Practice or Sanofi-Aventis. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

QUESTIONS (PLEASE CIRCLE ANSWER):

1. Data from clinical trials indicate that the response rate to the tyrosine kinase inhibitor erlotinib is higher in _____.

 - a. Smokers
 - b. Nonsmokers
2. The SWOG-S9504 Phase II study of consolidation therapy with docetaxel following cisplatin/etoposide/radiation therapy in patients with Stage III non-small cell lung cancer (NSCLC) reported a five-year survival rate of 25 to 30 percent.

 - a. True
 - b. False
3. Esophagitis is a common side effect of chemoradiation in the treatment of lung cancer.

 - a. True
 - b. False
4. Dr Lilenbaum's Phase II clinical trial for patients with NSCLC evaluates the combination of which three agents?

 - a. Cisplatin, docetaxel and bevacizumab
 - b. Cisplatin, gemcitabine and bevacizumab
 - c. Oxaliplatin, docetaxel and bevacizumab
 - d. Oxaliplatin, gemcitabine and bevacizumab
5. The TAX-326 trial showed an advantage in overall response rate with which of the following regimens when compared to cisplatin/vinorelbine?

 - a. Cisplatin/docetaxel
 - b. Carboplatin/docetaxel
6. In TAX-326 there was an improvement in quality of life associated with _____ when compared to cisplatin/vinorelbine.

 - a. Cisplatin/docetaxel
 - b. Carboplatin/docetaxel
7. According to published data, there may be no additional advantage gained in treating a patient with metastatic NSCLC with more than four cycles of carboplatin/docetaxel.

 - a. True
 - b. False
8. The Phase III trial ECOG-E4599 randomly assigned patients to receive carboplatin/paclitaxel with or without _____.

 - a. Erlotinib
 - b. Bevacizumab
 - c. Gefitinib
 - d. Gemcitabine
9. Results from the ECOG-E4599 study demonstrated an improvement in response rate, progression-free survival and overall survival in patients who received the experimental arm compared to those who received carboplatin/paclitaxel.

 - a. True
 - b. False
10. Side effects associated with prophylactic cranial radiation include:

 - a. Hair loss
 - b. Short-term memory loss
 - c. Fatigue
 - d. All of the above

EVALUATION FORM

Lung Cancer Update for Nurses — Issue 1, 2006

Postgraduate Institute for Medicine (PIM) respects and appreciates your opinions. To assist us in evaluating the effectiveness of this activity and to make recommendations for future educational offerings, please take a few minutes to complete this Evaluation Form. You must complete this Evaluation Form to receive acknowledgment of participation for this activity.

Please answer the following questions by circling the appropriate rating:

5 =
Outstanding

4 =
Good

3 =
Satisfactory

2 =
Fair

1 =
Poor

EXTENT TO WHICH PROGRAM ACTIVITIES MET THE IDENTIFIED GOAL

- To present the most current research developments in lung cancer and to provide the perspectives of medical oncologists, oncology nurses and patients on the diagnosis and treatment of lung cancer. 5 4 3 2 1

EXTENT TO WHICH PROGRAM ACTIVITIES MET THE IDENTIFIED OBJECTIVES

Upon completion of this activity, participants should be better able to:

- Describe the types and stages of lung cancer and the stage-based modalities utilized in the cancer. 5 4 3 2 1
- Discuss nursing management of disease-related symptoms and treatment side effects. 5 4 3 2 1
- Identify and counsel patients appropriate for treatment with adjuvant chemotherapy. 5 4 3 2 1
- Discuss key clinical trials in lung cancer in the adjuvant and metastatic settings. 5 4 3 2 1
- Discuss social stigma related to lung cancer and the impact on patients and healthcare professionals. 5 4 3 2 1
- Describe nursing interventions based on the biopsychosocial model in caring for patients with lung cancer. 5 4 3 2 1

EFFECTIVENESS OF THE INDIVIDUAL FACULTY MEMBERS

Faculty	Knowledge of subject matter	Effectiveness as an educator
Ann Fish-Steagall, RN, BSN, OCN	5 4 3 2 1	5 4 3 2 1
Rogerio C Lilenbaum, MD	5 4 3 2 1	5 4 3 2 1

OVERALL EFFECTIVENESS OF THE ACTIVITY

- Will assist me in improving patient care. 5 4 3 2 1
- Fulfilled my educational needs. 5 4 3 2 1
- Avoided commercial bias or influence. 5 4 3 2 1

IMPACT OF THE ACTIVITY

The information presented (check all that apply):

- Reinforced my current practice/treatment habits. Enhanced my current knowledge base.

EVALUATION FORM

Lung Cancer Update for Nurses — Issue 1, 2006

IMPACT OF THE ACTIVITY (CONTINUED)

Will the information presented cause you to make any changes in your practice?

- Yes No

If yes, please describe any change(s) you plan to make in your practice as a result of this activity:

.....
.....

How committed are you to making these changes?

(5 = very committed; 1 = not at all committed)..... 5 4 3 2 1

FUTURE ACTIVITIES

Do you feel future activities on this subject matter are necessary and/or important to your practice?

- Yes No

Please list any other topics that would be of interest to you for future educational activities:

.....
.....

Additional comments about this activity:

.....
.....

FOLLOW-UP

As part of our ongoing, continuous quality-improvement effort, we conduct postactivity follow-up surveys to assess the impact of our educational interventions on professional practice. Please indicate your willingness to participate in such a survey:

- Yes, I am willing to participate in a follow-up survey. No, I am not willing to participate in a follow-up survey.

REQUEST FOR CREDIT — please print clearly

Name: Degree:

Organization: Specialty:

Address:

City, State, Zip:

Telephone: Fax: Email:

Signature: Date:

Which of the following audio formats of this program did you use?

- Audio CDs Downloaded MP3s from website

LCUN106 To receive acknowledgment of participation in this activity, please complete the post-test and this evaluation/verification of participation and FAX to: (303) 790-4876 or mail to Postgraduate Institute for Medicine, 367 Inverness Parkway, Suite 225, Englewood, CO 80112. The post-test and evaluation form may also be completed at LungCancerUpdate.com/Nurses/CME.

Lung Cancer™

U P D A T E

Editor/CME Director	Neil Love, MD
Associate Editors	Richard Kaderman, PhD Kathryn Ault Ziel, PhD
Writers	Lillian Sklaver Poltorack, PharmD Douglas Paley
Continuing Education Administrator for Nursing	Sally Bogert, RNC, WHCNP
Content Validation	Margaret Peng Ginelle Suarez Erin Wall
Director, Creative and Copy Editing	Aura Herrmann
Creative Manager	Fernando Rendina
Associate Designer	Ben Belin
Graphic Designer	Jason Cunnius
Junior Designer	Shantia Daniel
Senior Production Editor	Alexis Oneca
Managing Production Coordinator	Tere Sosa
Copy Editors	Dave Amber Mary DiNunzio Rosemary Hulce Pat Morrissey/Havlin Carol Peschke Susan Petrone
Production Manager	Patricia Kappes
Audio Production	Frank Cesarano
Technical Services	Arly Ledezma
Web Master	John Ribeiro
Contact Information	Neil Love, MD Research To Practice One Biscayne Tower 2 South Biscayne Boulevard, Suite 3600 Miami, FL 33131 Fax: (305) 377-9998 Email: NLove@ResearchToPractice.net
For CE Information	Email: CME@ResearchToPractice.net

Copyright © 2006 Research To Practice. All rights reserved.

This program is supported by an education grant from Sanofi-Aventis.

The compact discs, internet content and accompanying printed material are protected by copyright. No part of this program may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording or utilizing any information storage and retrieval system, without written permission from the copyright owner.

The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management.

Any procedures, medications or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications or dangers in use, review of any applicable manufacturer's product information and comparison with recommendations of other authorities.

Lung Cancer™

U P D A T E

Copyright © 2006 Research To Practice.

This program is supported by an education grant from Sanofi-Aventis.



Co-sponsored by Postgraduate Institute for Medicine and Research To Practice.

Last review date: July 2006

Release date: July 2006

Expiration date: July 2007

Estimated time to complete the activity: 2 hours, 35 minutes